Jiha Lee JihaRheum
1 year 3 months ago
Should we start strong in PsA?
In the SPEED RCT (Coates et al), both early TNFi and combo csDMARDs outperformed step-up care in moderate-severe PsA. TNFi showed the most sustained benefit through 48w.
Abstract#OP0089
@RheumNow #EULAR2025
Mrinalini Dey DrMiniDey
1 year 3 months ago
First FcRn inhibitor in #IIM: In #ALKIVIA, SC efgartigimod PH20 improved TIS vs placebo at 24wks (50.45 vs 35.65, p=0.0004), with faster time to TIS≥20 (30 vs 71.5d) & TIS≥40 (113d vs NE). More major responders too (TIS>60: 34% vs 9.5%).
@RheumNow #EULAR2025 #OP0002 https://t.co/75BfbXoVpL
Dr. John Cush RheumNow
1 year 3 months ago
Muscle biopsies form 3 treatment-naïve juvenile dermatomyositis (JDM) finds transcriptomic evidence of mitochondrial dysfunction consistently in JDM muscle, independent of interferon-driven inflammation. Treating mitochondrial dysfunction may improve JDM outcomes https://t.co/u5tMhT23si
Choice is not just good, it is often necessary, and secukinumab promises just that in both PMR and GCA.
Bella Mehta bella_mehta
1 year 3 months ago
How to patients with rheumatic diseases consume online health information?
78% used internet for health information
50% use it atleast a month
66% found online information superior
41% used social media!
80% using it to find treatment optio ns!
@rheumnow #EULAR2025 https://t.co/diMCloFFVF
David Liew drdavidliew
1 year 3 months ago
Rheumatologists can’t ignore hypereosinopilic syndrome anymore, not when it borders on our diseases and therapies. Great takeaways on subtypes and therapies from Giacomo Emmi in an elegant talk #EULAR2025 @RheumNow https://t.co/vqZajY0nUp
Bella Mehta bella_mehta
1 year 3 months ago
Platelet rich plasma in knee #OA! They asked this to #ChatGPT ...
Whatever is out there on the internet will contaminate responses which pts rely on..:(
@rheumnow #EULAR2025 https://t.co/stlbhHp3zp
Nelly ZIADE 🍀 Nellziade
1 year 3 months ago
Treatment of MAS, or the bête noire in Still's disease, presented at the Plenary session by Peter Nigrovic
#Plenary room
#EULAR2025
@RheumNow https://t.co/S4SG2VflNg
Bella Mehta bella_mehta
1 year 3 months ago
#AI can be a valuable tool, but needs to be reliable. Lupus100 and #lupusGPT created with vetted sources,
#Easylupus is condensed, even more easy to read
It's better to ask your patients to use it as a reliable source!
#EULAR2025 @RheumNow https://t.co/FbYYm1dB8E
Jiha Lee JihaRheum
1 year 3 months ago
Debuting Fishbowl sessions at #EULAR2025 🔄💊
Lively audience engaging session in A1 on how drug prices influence treatment decisions; real-world tensions between cost, access, & physician autonomy. Transparent, interactive, and packed!
@RheumNow | Location: A1 | #EULAR2025 https://t.co/jVbviLuTZK
Dr. John Cush RheumNow
1 year 3 months ago
RheumNow’s expanded coverage of the #EULAR2025 Annual meeting is sponsored in part by Johnson & Johnson and UCB. All content chosen by RheumNow & its Faculty
Janet Pope Janetbirdope
1 year 3 months ago
#MTX in new #PMR?!
RCT of #MTX was negative in early #PMR - no effect on #steroid #tapering
ACR24 #1697
At #EULAR2025
👇
+RCT of #methotrexate in PMR <8wks #steroids #Rx MTX 25 mg/wk v #placebo
N=64
⬆️GC remission ✅80% v 46%
⬇️relapse w MTX
🤔
Abst0064 @RheumNow #EULAR2025
Aurelie Najm AurelieRheumo
1 year 3 months ago
#EULAR2025 Opening Plenary
C. Dejaco, the EULAR Congress chair presents the @eular_org congress in numbers:
4 days
300+ Invited speakers
170+ Scientific sessions
40 Oral presentations
8 Poster tours
12000+ Attendees
@RheumNow https://t.co/hX1ABtSio2
We’re seeing more patients develop rheumatic diseases for the first time in their 60s, 70s, or beyond. But are these truly the same diseases we see in younger adults, or do they behave differently, shaped by age-related biology, comorbidity, and the biases that influence medical decision-making? Several abstracts presented at EULAR 2025 challenge us to reconsider how we diagnose and treat rheumatic disease in older adults.
The race is on for the first chimeric antigen receptor (CAR)-based therapy to be approved for the treatment of systemic lupus erythematosus. Its main principle is to induce deep B-cell depletion, with the hope to reset the B-cell aberrant immunity for a sustained clinical remission. At EULAR 2025 in Barcelona, several advances of CAR-based therapies will be presented.
